Biologics & Biosimilars

FDA Approves Risankizumab, Adds Stronger Warning to Sleep Medications

May 29, 2019 • By Michele B. Kaufman, PharmD, BCGP

British Columbia Will Be First Canadian Province to Switch Patients to Biosimilars

May 29, 2019 • By Allison Martell & Allison Lampert

Common Characteristics in RA Patients Who Don’t Respond to Biologics

May 18, 2019 • By Vanessa Caceres

Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol

May 7, 2019 • By Michele B. Kaufman, PharmD, BCGP

Osteoporotic Fracture Rates Similar with Denosumab, Alendronate in Real World

April 25, 2019 • By Megan Brooks

IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results

April 22, 2019 • By Will Boggs MD

Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis

April 15, 2019 • By Michele B. Kaufman, PharmD, BCGP

Mirikizumab Promising for Plaque Psoriasis

April 10, 2019 • By Michele B. Kaufman, PharmD, BCGP

Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients

April 3, 2019 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Guselkumab Injector

March 20, 2019 • By Michele B. Kaufman, PharmD, BCGP

1
2
3
…
30
Next Page »